【摘要】 目的:评价阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效及不良反应。方法:回顾性分析2015年7月至2016年11月就诊于天津医科大学肿瘤医院,经病理学确诊为晚期三阴性乳腺癌,既往接受过两线以上化疗后疾病进展(progressive disease,PD)、服用阿帕替尼500 mg/d治疗的8例患者临床资料,所有患者均在接受2个周期以上治疗后评价疗效,观察PD时间、有效率、临床获益率及不良反应。结果:8例患者共接受平均4个周期的治疗,经过中位随访时间为8(4~11)个月,其中部分缓解(partial remission,PR)4例,疾病稳定(stable disease,SD)3例,PD 1例;疾病控制率(disease control rate,DCR)为87.5%(7/8),客观缓解率(objective response rate,ORR)为50%(4/8),平均无进展生存期(progression free survival,PFS)为4.2个月。不良反应为手足综合征(3/8)、骨髓抑制(4/8)、高血压(2/8)、蛋白尿(3/8)、咯血(1/8)、恶心(2/8)、乏力(2/8)等。结论:阿帕替尼在三阴性乳腺癌的治疗中可获得一定的疗效及生存获益,且安全性好,不良反应可控。更多还原

【Abstract】 Objective:To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer.Methods:Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology,who were previously treated with anthracycline,taxane,gemcitabine,capecitabine,and 500 mg/d apatinib in our hospital from July 2015 to November 2016,were retrospectively analyzed.The time of disease progress,effective rate,clinical benefits,and side effects were observed.Results:Eight patients were administrated with an average of 4 treatment cycles,and the effects were evaluated after 2 weeks.Four patients exhibited partial remission,3 had a stable disease,and 1 had a progressive disease.The disease control rate was 87.5%,and the median progression free survival was 4.2 months.The main side effects were hand-foot syndrome(3/8),bone marrow arrest(4/8),hypertension(2/8),proteinuria(3/8),hemoptysis(1/8),nausea(2/8),and fatigue(2/8).Most of these side effects were tolerable.Conclusion:Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.更多还原